A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder
Latest Information Update: 12 Jan 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Binge-eating disorder
- Focus Adverse reactions
- Acronyms S.T.O.P
- Sponsors TRYP Therapeutics
- 08 Jan 2024 Status changed from active, no longer recruiting to completed, according to a Tryp Therapeutics media release.
- 12 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2022 According to a TRYP Therapeutics media release, interim data analysis for the first 5 patients is scheduled to be available in January of 2023